List of Excipients in Branded Drug TUZISTRA XR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Aytu BioPharma Inc	TUZISTRA XR	codeine polistirex and chlorpheniramine polistirex	69654-480	CITRIC ACID ACETATE	2029-03-29
Aytu BioPharma Inc	TUZISTRA XR	codeine polistirex and chlorpheniramine polistirex	69654-480	D&C RED NO. 30	2029-03-29
Aytu BioPharma Inc	TUZISTRA XR	codeine polistirex and chlorpheniramine polistirex	69654-480	ETHYL MALTOL	2029-03-29

TUZISTRA XR Excipient Strategy and Commercial Opportunities

Last updated: September 5, 2026

Tuzistra XR is an extended-release oral suspension combining codeine polistirex and chlorpheniramine polistirex. Its commercial differentiation depends on drug-resin complexes, controlled sedimentation, palatability, preservative performance, and 12-hour dosing rather than on a novel active ingredient. The strongest excipient opportunities are sugar reduction, improved taste masking, lower sedimentation, alternative preservative systems, and pediatric-risk-sensitive packaging.

What is Tuzistra XR and how does its formulation work?

Tuzistra XR is a prescription extended-release oral suspension for relief of cough and upper-respiratory symptoms associated with allergies or the common cold. Each 5 mL contains codeine polistirex equivalent to 10 mg of codeine and chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine. The product is dosed every 12 hours, unlike immediate-release codeine and antihistamine cough products that generally require more frequent administration.[1]

The formulation uses polistirex complexes. These are drug-resin systems in which ionized drug molecules associate with an ion-exchange resin. Release is influenced by resin chemistry, particle size, coating or matrix behavior, gastrointestinal ionic conditions, and suspension processing.

The formulation must meet several competing requirements:

• Maintain a reproducible 12-hour release profile.
• Keep the drug-resin particles uniformly distributed during storage and dosing.
• Prevent excessive sedimentation or hard caking.
• Mask the bitter taste of codeine and chlorpheniramine.
• Maintain preservative effectiveness in a multidose liquid.
• Support accurate dosing through the supplied oral dosing device.
• Preserve chemical and microbial stability after opening.

These requirements limit the ability of a generic manufacturer to substitute excipients without repeating substantial formulation and stability work.

What excipients are used in Tuzistra XR?

The FDA prescribing information identifies a conventional liquid-suspension excipient platform that includes viscosity control, buffering, sweetening, preservation, flavoring, and solvent components.[1]

Excipient or excipient class	Likely formulation function
Xanthan gum	Suspending and rheology-control agent
Sucrose	Sweetener and mouthfeel modifier
Glycerin	Humectant, cosolvent, and mouthfeel agent
Propylene glycol	Cosolvent and flavor-solubilizing agent
Methylparaben	Antimicrobial preservative
Citric acid	Acidulant and pH adjustment
Sodium citrate dihydrate	Buffering agent
Edetate disodium	Chelating agent that can support preservative performance
Purified water	Continuous liquid phase
Natural and artificial flavors	Taste masking and product acceptability
FD&C Yellow No. 6	Colorant

The precise performance of the product comes from the interaction of these ingredients with the polistirex drug complexes. Xanthan gum concentration, hydration conditions, mixing energy, pH, ionic strength, and particle-size distribution can materially affect settling and redispersibility.

Which excipients create the greatest formulation barrier?

Drug-resin complex and particle engineering

The central technical barrier is the polistirex system, not the flavor or color package. A competing product must reproduce the release behavior of both active ingredients while maintaining a stable suspension.

Changes in resin type, cross-link density, drug loading, particle size, or processing conditions can alter:

• Initial drug release.
• Release during the middle portion of the dosing interval.
• Terminal release.
• Sedimentation rate.
• Mouthfeel and grittiness.
• Dose uniformity after storage.
• Drug recovery during assay and dissolution testing.

A manufacturer using a different resin may need an extensive comparative in vitro package and could face difficulty establishing pharmaceutical equivalence.

Xanthan gum and suspension behavior

Xanthan gum is commercially attractive because it produces strong low-shear viscosity and shear-thinning behavior. The product can remain relatively viscous at rest while flowing through a dosing device when shaken or poured.

The concentration must remain within a narrow practical range. Too little xanthan gum can create rapid settling and dose nonuniformity. Too much can cause:

• Difficult pouring.
• Poor syringe withdrawal.
• A heavy or slimy mouthfeel.
• Incomplete redispersion.
• Manufacturing challenges during deaeration and filling.

Alternative suspending agents, including microcrystalline cellulose-based systems, sodium carboxymethylcellulose, or combinations with other gums, could create a differentiated formulation. They also create comparability risk because their yield stress, hydration rate, and interaction with drug-resin particles differ from xanthan gum.

Sucrose and palatability

Sucrose improves taste and body but creates a clear opportunity for sugar-reduced or sugar-free versions. A replacement system would need to offset the loss of sucrose’s sweetness, viscosity, and mouthfeel.

Potential substitutes include:

• Sorbitol.
• Glycerin at an increased level.
• Sucralose.
• Acesulfame potassium.
• Specialized flavor-modifier systems.
• Polyol combinations.

A sugar-free version could target diabetic patients, caregivers seeking lower-sugar products, and institutional formularies. The commercial value depends on whether the replacement maintains acceptable taste without increasing gastrointestinal adverse effects or destabilizing the suspension.

Methylparaben and preservative systems

Methylparaben is a conventional preservative, but preservative systems are a potential reformulation point. Options may include potassium sorbate, sodium benzoate, or combinations of preservatives, subject to pH compatibility and microbiological performance.

A preservative change would require testing under USP antimicrobial effectiveness standards and evaluation of preservative distribution between the aqueous phase and suspended particles. The product’s pH and chelator content can materially influence performance.

A preservative-free multidose product would be commercially difficult because it would require a validated microbiological control strategy, specialized packaging, or a single-use presentation. A unit-dose or sachet format could reduce preservative exposure but would raise packaging and distribution costs.

What commercial opportunities exist for Tuzistra XR excipients?

Sugar-free or reduced-sugar Tuzistra XR

The most visible lifecycle opportunity is a sugar-free or reduced-sugar presentation. Such a product could preserve the extended-release drug-resin platform while changing the sweetener and mouthfeel system.

The principal development risks are taste, viscosity, osmolality, preservative compatibility, and dose uniformity after storage. A sugar-free version would also need a clear labeling and pharmacy-dispensing strategy to avoid confusion with the original formulation.

Improved taste masking

Codeine-containing liquids face a strong palatability challenge. Flavoring alone may be insufficient because codeine and chlorpheniramine can produce persistent bitterness.

Commercially relevant approaches include:

• More effective flavor-modifier systems.
• Coated drug-resin particles.
• Ion-exchange resins with lower oral drug release.
• Multiparticulate systems with improved mouthfeel.
• Lower-grit suspension architectures.
• Unit-dose packaging that limits repeated exposure to an opened bottle.

Taste masking has value in both adult and adolescent markets, although regulatory restrictions materially limit pediatric positioning for opioid-containing cough products.

Ready-to-use unit-dose packaging

Tuzistra XR is a multidose suspension, so a unit-dose sachet, stick pack, or small cup could address portability, dosing convenience, and microbial-control concerns.

A unit-dose product could support:

• Urgent-care and clinic dispensing.
• Travel use.
• Institutional settings.
• Reduced contamination after opening.
• More consistent dosing if the product is premeasured.

The tradeoff is higher packaging cost and potential compatibility work between the formulation and the package. Sorption, leachables, seal integrity, and suspension homogeneity across the fill volume would require evaluation.

Improved dosing-device compatibility

The formulation’s rheology directly affects dosing accuracy. A proprietary oral syringe or dosing cup designed for viscous suspensions could reduce underdosing, overdosing, and residual product in the bottle.

Device-related opportunities include:

• Low-dead-volume oral syringes.
• Integrated bottle adapters.
• Child-resistant closures with easier caregiver handling.
• Graduated devices calibrated in 5 mL increments.
• Packaging that requires less vigorous shaking.

A device change may be commercially useful without changing the active formulation, but combination-product and labeling considerations still apply.

Stability and cold-chain reduction

An excipient system that improves chemical stability at room temperature could reduce logistics costs and pharmacy handling constraints. Relevant variables include pH, oxygen exposure, metal-ion control, light protection, and preservative stability.

Edetate disodium may help control trace-metal catalysis, while the buffer system can limit pH drift. A reformulator would need to confirm that any pH adjustment does not change drug binding to the resin or alter release kinetics.

What FDA regulatory issues affect excipient reformulation?

Tuzistra XR is an FDA-approved prescription drug product containing opioid and antihistamine active ingredients. A generic applicant would generally need to demonstrate pharmaceutical equivalence and bioequivalence under the applicable abbreviated new drug application pathway, while also addressing the complexity of the extended-release suspension.[2]

The main regulatory questions are:

Issue	Commercial effect
Active ingredient equivalence	Limits changes to drug-resin complexes
Extended-release performance	Requires comparative release data
Suspension dose uniformity	Creates testing burden after storage and shaking
Preservative effectiveness	Required for multidose liquid presentations
Inactive ingredient changes	May require safety and compatibility justification
Flavor and color changes	Can support differentiation but affect labeling and acceptability
Oral-device changes	Can affect delivered dose and human-factor performance
Opioid labeling	Restricts pediatric and broad consumer positioning

Tuzistra XR labeling includes opioid-related warnings and pediatric restrictions. The product is contraindicated in certain pediatric settings and carries respiratory-depression risks associated with codeine-containing medicines.[1] Those restrictions reduce the addressable market for pediatric reformulation claims, even if taste and dosing improvements are technically feasible.

What patent and exclusivity issues affect commercial entry?

The commercial barrier is likely to be distributed across several rights categories:

1. Drug-resin complex composition claims.
2. Extended-release oral suspension claims.
3. Formulation claims covering suspending agents, buffers, sweeteners, preservatives, or ratios.
4. Method-of-use claims for treating cough or upper-respiratory symptoms.
5. Manufacturing-process claims covering resin loading, particle-size control, or suspension processing.
6. Device or packaging claims.

An excipient change does not automatically avoid patent risk. A formulation may use different ingredients but still fall within claims directed to the active drug-resin complex, release profile, dosage form, or manufacturing process.

A generic applicant would also need to evaluate FDA Orange Book listings and any listed patent certifications associated with the reference listed drug. A Paragraph IV certification could trigger patent litigation and a potential 30-month stay under the Hatch-Waxman framework if the sponsor brings a timely infringement action.[3]

The strongest design-around strategy would separate the technical changes:

• Use a noninfringing resin system.
• Develop a distinct particle-size distribution.
• Replace the sugar and preservative platform.
• Establish an independent release mechanism.
• Avoid claimed excipient ratios and manufacturing sequences.
• Use alternative packaging and dosing components.

The risk is that each change can create a new bioequivalence or stability problem. A simple excipient substitution is commercially attractive only if it does not materially change release or dose uniformity.

How does Tuzistra XR compare with competing cough liquids?

Product type	Dosing pattern	Main differentiation	Excipient opportunity
Tuzistra XR	Every 12 hours	Extended-release codeine and chlorpheniramine suspension	Sugar-free, taste masking, device, unit-dose packaging
Immediate-release codeine cough liquids	More frequent dosing	Low formulation complexity and broad generic availability	Limited differentiation; price competition
Non-opioid antitussive liquids	Product-dependent	Avoid opioid restrictions	Stronger consumer and pediatric positioning
Antihistamine-only liquids	Product-dependent	Allergy symptom treatment without codeine	Lower controlled-substance risk
Dextromethorphan products	Product-dependent	Non-opioid cough suppression	High generic and OTC competition

Tuzistra XR’s commercial advantage is dosing frequency. Its commercial disadvantage is the regulatory and safety burden associated with codeine. Non-opioid products can compete for patients, prescribers, and payers even when they lack the same extended-release profile.

What is the commercial outlook for an excipient-focused Tuzistra XR strategy?

The most realistic opportunities are incremental lifecycle products rather than a completely new excipient platform.

Opportunity	Technical difficulty	Commercial potential
Sugar-reduced formulation	Medium	Medium
Sugar-free formulation	Medium to high	Medium
Improved taste masking	Medium	Medium to high
Unit-dose packaging	Medium	Medium
New oral dosing device	Low to medium	Medium
Preservative reformulation	Medium	Low to medium
New resin-release system	High	High, but high regulatory risk
Pediatric-focused positioning	High regulatory constraint	Limited
Non-opioid reformulation	Very high	Could require a new product rather than a lifecycle version

The strongest near-term strategy is a combination of improved palatability, sugar reduction, and dosing-device optimization while preserving the established drug-resin release system. A new resin architecture offers greater differentiation but carries the highest development, bioequivalence, and patent risk.

Key Takeaways

• Tuzistra XR depends on codeine polistirex and chlorpheniramine polistirex complexes for 12-hour release.
• Xanthan gum, sucrose, glycerin, propylene glycol, methylparaben, citrate buffer, edetate disodium, flavors, and colorant form the principal excipient platform.
• The most valuable excipient opportunities are sugar-free reformulation, taste masking, improved redispersibility, unit-dose packaging, and dosing-device integration.
• Drug-resin chemistry and particle engineering create a stronger technical barrier than conventional sweetener or flavor changes.
• Any generic or reformulated product must address extended-release comparability, dose uniformity, preservative effectiveness, and suspension stability.
• Codeine-related safety restrictions narrow pediatric and mass-market opportunities.
• Patent risk may cover the resin complex, release profile, formulation, manufacturing process, method of use, and packaging rather than excipients alone.
• A differentiated formulation is most commercially attractive when it improves adherence without changing the established 12-hour release mechanism.

FAQs

Can Tuzistra XR be reformulated without changing its active ingredients?

Yes. A reformulation could change sweeteners, flavors, preservatives, suspending agents, packaging, or dosing devices. Any change that affects release, dose uniformity, stability, or bioequivalence would require regulatory support.

Is xanthan gum essential to the Tuzistra XR formulation?

Xanthan gum is an important suspending and rheology-control agent, but it is not necessarily the only technically feasible option. A replacement would need to reproduce redispersibility, viscosity, sedimentation control, dosing behavior, and release performance.

Would a sugar-free Tuzistra XR have major commercial value?

It could create a differentiated lifecycle product, particularly for patients seeking lower-sugar medicines. Its value would depend on acceptable taste, stable preservation, and unchanged extended-release performance.

Can an excipient change avoid Tuzistra XR patent claims?

Not necessarily. Patent claims may cover the drug-resin complex, release characteristics, manufacturing process, dosage form, or method of use. Excipient substitution alone does not establish freedom to operate.

Why is a generic extended-release suspension harder to develop than an immediate-release cough liquid?

The applicant must match active-ingredient strength and bioavailability while controlling particle size, resin binding, sedimentation, redispersibility, viscosity, and release over the full dosing interval. Immediate-release liquids generally have fewer release-control variables.

References

1. U.S. Food and Drug Administration. (n.d.). Tuzistra XR prescribing information: Codeine polistirex and chlorpheniramine polistirex extended-release oral suspension. FDA-approved labeling.

2. U.S. Food and Drug Administration. (2023). Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA: Guidance for industry. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.